$ANNA
AleAnna, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024097353 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $256.4K
YoY Change -69.83%
Operating Profit -$256.4K
YoY Change -69.83%
Interest Expense $179.3K
YoY Change -85.04%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$77.18K
YoY Change -122.18%
Income Tax
% Of Pretax Income
Net Earnings -$77.18K
YoY Change -122.18%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.01
COMMON SHARES
Basic Shares Outstanding 4.590M shares 4.590M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.520K
YoY Change -86.36%
Cash & Equivalents $9.520K
Short-Term Investments
Other Short-Term Assets $22.54K
YoY Change -82.42%
Inventory
Prepaid Expenses $22.54K
Receivables
Other Receivables
Total Short-Term Assets $32.06K
YoY Change -83.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $13.71M
YoY Change -43.07%
Other Assets
YoY Change
Total Long-Term Assets $13.71M
YoY Change -43.07%
TOTAL ASSETS
Total Short-Term Assets $32.06K
Total Long-Term Assets $13.71M
Total Assets $13.75M
YoY Change -43.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.335M
YoY Change 24.93%
Accrued Expenses $322.0K
YoY Change -58.78%
Deferred Revenue
YoY Change
Short-Term Debt $1.006M
YoY Change 151.5%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.241M
YoY Change 24.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.241M
Total Long-Term Liabilities $0.00
Total Liabilities $4.241M
YoY Change 24.14%
SHAREHOLDERS EQUITY
Retained Earnings -$4.109M
YoY Change 31.76%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.109M
YoY Change
Total Liabilities & Shareholders Equity $13.75M
YoY Change -43.4%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$77.18K
YoY Change -122.18%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$288.1K
YoY Change -4.95%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 295.0K
YoY Change 47.5%
NET CHANGE
Cash From Operating Activities -288.1K
Cash From Investing Activities 0.000
Cash From Financing Activities 295.0K
Net Change In Cash 6.890K
YoY Change -106.68%
FREE CASH FLOW
Cash From Operating Activities -$288.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41164
dei Entity Registrant Name
EntityRegistrantName
SWIFTMERGE ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1582153
dei Entity Address Address Line1
EntityAddressAddressLine1
4318 Forman Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
Toluca Lake
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91602
dei City Area Code
CityAreaCode
(424)
dei Local Phone Number
LocalPhoneNumber
431-0030
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4589913 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9520 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148349 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
22543 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
32063 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
148349 usd
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
13713477 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
24376178 usd
CY2024Q3 us-gaap Assets
Assets
13745540 usd
CY2023Q4 us-gaap Assets
Assets
24524527 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2334642 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2015734 usd
CY2024Q3 ivcp Accrued Offering Cost
AccruedOfferingCost
311430 usd
CY2023Q4 ivcp Accrued Offering Cost
AccruedOfferingCost
311430 usd
CY2024Q3 ivcp Due To Sponsor
DueToSponsor
2284 usd
CY2023Q4 ivcp Due To Sponsor
DueToSponsor
2284 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
321994 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
185310 usd
CY2024Q3 us-gaap Liabilities
Liabilities
4240866 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3170274 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4109365 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2922487 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4108803 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2921925 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13745540 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24524527 usd
CY2024Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
256436 usd
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
850085 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1186878 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3281394 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-256436 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-850085 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1186878 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3281394 usd
CY2024Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
179258 usd
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
1198052 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
663121 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
6212416 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-77178 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
347967 usd
us-gaap Net Income Loss
NetIncomeLoss
-523757 usd
us-gaap Net Income Loss
NetIncomeLoss
2931022 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2921925 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
309906 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
326773 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-326773 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-91069 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3322900 usd
CY2024Q2 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
173957 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-355510 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3852367 usd
CY2024Q3 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
179258 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-77178 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4108803 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
163250 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2328946 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1110240 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1055456 usd
CY2023Q2 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2685418 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1472815 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2268059 usd
CY2023Q3 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1198052 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
347967 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3118144 usd
us-gaap Net Income Loss
NetIncomeLoss
-523757 usd
us-gaap Net Income Loss
NetIncomeLoss
2931022 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
663121 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
6212416 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
22543 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-385954 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
318908 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1817266 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
136684 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
277037 usd
ivcp Increase Decrease In Accrued Liabilities Related Party
IncreaseDecreaseInAccruedLiabilitiesRelatedParty
9000 usd
ivcp Increase Decrease In Accrued Liabilities Related Party
IncreaseDecreaseInAccruedLiabilitiesRelatedParty
9000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-744829 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-792137 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11325822 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
211918104 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11325822 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
211918104 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
11325822 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
211918104 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
406000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
400000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
200000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10719822 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-211518104 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-138829 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-392137 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148349 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
461914 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9520 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69777 usd
us-gaap Stock Issued1
StockIssued1
326773 usd
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
663121 usd
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
6212416 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
337 usd
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2021-02-03
ivcp Term Of Restricted Investments
TermOfRestrictedInvestments
P185D
CY2024Q3 ivcp Number Of Operating Businesses Included In Initial Business Combination
NumberOfOperatingBusinessesIncludedInInitialBusinessCombination
1 pure
CY2024Q3 ivcp Fair Market Value As Percentage Of Net Assets Held In Trust Account Included In Initial Business Combination
FairMarketValueAsPercentageOfNetAssetsHeldInTrustAccountIncludedInInitialBusinessCombination
0.80 pure
CY2024Q3 us-gaap Minimum Net Worth Required For Compliance
MinimumNetWorthRequiredForCompliance
5000001 usd
CY2024Q3 ivcp Percentage Of Public Shares That Can Be Redeemed Without Prior Consent
PercentageOfPublicSharesThatCanBeRedeemedWithoutPriorConsent
0.15 pure
CY2024Q3 ivcp Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed With In Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithInInitialCombinationPeriod
1 pure
ivcp Period To Complete Business Combination From Closing Of Initial Public Offering
PeriodToCompleteBusinessCombinationFromClosingOfInitialPublicOffering
P18M
ivcp Period To Redeem Public Shares If Business Combination Is Not Completed Within Initial Combination Period
PeriodToRedeemPublicSharesIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
P10D
CY2024Q3 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000 usd
CY2024Q3 ivcp Redemption Price Per Share
RedemptionPricePerShare
10.1
us-gaap Conversion Of Stock Description
ConversionOfStockDescription
one-for-one
CY2024Q3 ivcp Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.1
ivcp Public Price Per Share
PublicPricePerShare
10.1
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
65098476 shares
CY2024Q3 us-gaap Cash
Cash
9520 usd
CY2024Q3 ivcp Working Capital Surplus
WorkingCapitalSurplus
4208803 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of the financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9520 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148349 usd
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
13713477 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
24376178 usd
CY2024Q3 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000 usd
CY2024Q3 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
179258 usd
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
26958716 usd
ivcp Other Offering Costs
OtherOfferingCosts
977966 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20600000 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Deposits
Deposits
2600000 usd
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
85000 usd
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
26000 usd
CY2024Q3 ivcp Due To Sponsor
DueToSponsor
2284 usd
CY2023Q4 ivcp Due To Sponsor
DueToSponsor
2284 usd
CY2023Q3 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
3000 usd
us-gaap Administrative Fees Expense
AdministrativeFeesExpense
9000 usd
CY2024Q1 ivcp Transaction Fee Percentage
TransactionFeePercentage
0.05 pure
CY2024Q1 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
3000000 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Conversion Of Stock Description
ConversionOfStockDescription
one-for-one
CY2024Q3 us-gaap Management Fee Payable
ManagementFeePayable
117000 usd
CY2024Q3 ivcp Additional Fee Remaining Amount
AdditionalFeeRemainingAmount
83600 usd
ivcp Amount Agreed To Forgo Subject To The Availability Of Funds
AmountAgreedToForgoSubjectToTheAvailabilityOfFunds
5750000 usd
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2023Q2 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Stock Issued1
StockIssued1
usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
usd
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001845123

Files In Submission

Name View Source Status
ivcp-20240930_cal.xml Edgar Link unprocessable
0001213900-24-097353-index-headers.html Edgar Link pending
0001213900-24-097353-index.html Edgar Link pending
0001213900-24-097353.txt Edgar Link pending
0001213900-24-097353-xbrl.zip Edgar Link pending
ea0220903-10q_swiftmerge.htm Edgar Link pending
ea022090301ex31-1_swift.htm Edgar Link pending
ea022090301ex31-2_swift.htm Edgar Link pending
ea022090301ex32-1_swift.htm Edgar Link pending
ea022090301ex32-2_swift.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ivcp-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ivcp-20240930_def.xml Edgar Link unprocessable
ivcp-20240930_lab.xml Edgar Link unprocessable
ivcp-20240930_pre.xml Edgar Link unprocessable
ea0220903-10q_swiftmerge_htm.xml Edgar Link completed